Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg
https://doi.org/10.37489/2588-0519-2021-4-80-84
Abstract
Introduction. To date, 20 COVID-19 vaccines have been registered and used in the world, three of them have been developed in the Russian Federation. The results of clinical studies of the domestic vaccine «Sputnik V» were published in the international journal «The Lancet». However, there are not so many publications on the effectiveness of Russian vaccines in real practice, mainly from Argentina. At the beginning of August 2021, the Health Committee in St. Petersburg published data on the number of people who became ill with COVID-19 after vaccination in open sources.
Aim. To evaluate the effectiveness of vaccination against COVID-19 based on real world data.
Materials and methods. The data source was information on the number of persons, the number of persons vaccinated in St. Petersburg, as well as those who became ill after vaccination, as of 07/23/2021.
Results. The risk of developing a new coronavirus infection among patients who have passed the full course (2 injections) of vaccination is 6.0–7.0 times lower (95 % CI: 6.34–7.24) compared with the group of patients who have not passed the full course (2 injections) of vaccination against COVID-19.
Conclusions. Vaccination against COVID-19 is an effective way to reduce the risk of disease.
About the Authors
A. A. Kurylev
FSBEI HE I. P. Pavlov SPbSMU MOH Russia
Russian Federation
Russian Federation
Kurylev Alexey A., Cand. Sci. Med., Assistant of professor Department of Clinical Pharmacology and Evidence-Based Medicine
SPIN code: 4470-7845
Saint-Petersburg
A. A. Zhuravkov
FSBEI HE I. P. Pavlov SPbSMU MOH Russia
Russian Federation
Russian Federation
Zhuravkov Andrei A., Post-graduate student, Department of Clinical Pharmacology and Evidence-Based Medicine
Saint-Petersburg
A. S. Kolbin
FSBEI HE I. P. Pavlov SPbSMU MOH Russia
Russian Federation
Russian Federation
Kolbin Alexey S., Dr. Sci. (Med.), Professor, Head of the Department of Clinical Pharmacology and Evidence-Based Medicine
SPIN code: 7966-0845
Saint-Petersburg
References
1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19– 11 March 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-sopening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (cited 17 September 2021).
2. Covid-19 living Data. Covid-nma.com. 2021. Available from: https:// covid-nma.com/dataviz/ (updated 2021 September 15; cited 17 September 2021).
3. Fangjun Z, Abigail S, Jay W, Mark M, Li YW, Adriana L, Matthew M, Trudy VM, Margaret C, Lance R. Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009. Pediatrics. Apr 2014;133(4):577–85. doi: 10.1542/peds.2013-0698. Available from: https://pediatrics.aappublications.org/content/133/4/577.
4. Covid-19 living Data. Covid-nma.com. vaccines/mapping/ 2021. Available from: https://covid-nma.com/vaccines/mapping/ (updated 2021 September 15; cited 17 September 2021).
5. Covid-19 vaccine tracker. Covid-19 vaccine tracker by the Milken Institute. Available from: https://www.covid-19vaccinetracker.org/ (updated 2021 September 1; cited 17 September 2021).
6. Государственный реестр лекарственных средств. 2021. Государственный реестр лекарственных средств. 2020. Доступ по ссылке: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d494c688-0bc6-4c30-9e81-23f043ceb43e&t=%C2%A0 (доступ от 17.09.2021).
7. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 4;396(10255):887–97. doi: 10.1016/S0140-6736(20)31866-3
8. Управление клиническими исследованиями / под ред. Белоусова Д. Ю., Зырянова С. К., Колбина А. С.– М.: Буки Веди: Издательство ОКИ, 2017. [Upravlenie klinicheskimi issledovaniyami. Ed by Belousov DYu, Zy`ryanov SK, Kolbin AS. Moscow: Buki Vedi: Publishing House OKI, 2017. (In Russ).].
9. Материалы сайта фонтанка.ру. 2021. В Смольном рассказали, какая из трёх вакцин защитила петербуржцев от коронавируса лучше всего. Доступ по ссылке: https://www.fontanka.ru/2021/08/02/70057487/ (доступ от 17.09.2021).
10. petrostat.gks.ru 2021. Федеральная служба государственной статистики. Доступ по ссылке: https://petrostat.gks.ru/storage/mediabank/Числ.СПб%20на%2001.01.2020.pdf (доступ от 17.09.2021).
11. Реброва О. Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA.– М.: Медиа - Сфера, 2002.– 312 с. [Rebrova OYu. Statisticheskij analiz medicinskih dannyh. Primenenie paketa prikladnyh programm STATISTICA. Moscow: MediaSfera, 2002. 312 p. (In Russ).].
12. VassarStats: Website for Statistical Computation. Available http:// vassarstats.net/ (updated 2021 September 15; cited 17 September 2021).
13. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 2;397(10275):671–81. doi: 10.1016/S0140-6736(21)00234-8
14. Soledad González, Santiago Olszevicki, Martín Salazar, Ana Calabria, Lorena Regairaz. Effectiveness of the first component of Gam-COVIDVac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60–79: a retrospective cohort study in Argentina. EClinicalMedicine. 2021;40:101–26. doi: 10.1016/j.eclinm.2021.101126
15. Official website of the Argentine State. Available from: https://www.argentina.gob.ar/noticias/ministros-de-salud-de-todo-el-pais-consensuaronredoblar-esfuerzos-para-completar-los (cited 17 September 2021).
16. Nogrady B. Mounting evidence suggests Sputnik COVID vaccine is safe and effective. Nature. 2021 Jul;595(7867):339–40. doi: 10.1038/d41586-021-01813-2
17. Официальный сайт первой российской вакцины от коронавируса «Спутник V». Доступ по ссылке: https://sputnikvaccine.com/rus/newsroom/pressreleases/effektivnost-vaktsiny-sputnik-v-sostavila-97-6-po-rezultatamanaliza-dannykh-3-8-mln-vaktsinirovanny/ (доступ от 17.09.2021).
18. Ryzhikov AB, Ryzhikov ЕА, Bogryantseva MP, Usova SV, Danilenko ED, Nechaeva EA, Pyankov OV, Pyankova OG, Gudymo AS, Bodnev SA, Onkhonova GS, Sleptsova ES, Kuzubov VI, Ryndyuk NN, Ginko ZI, Petrov VN, Moiseeva AA, Torzhkova PYu, Pyankov SA, Tregubchak TV, Antonec DV, Gavrilova EV, Maksyutov RA. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Russian Journal of Infection and Immunity. 2021;11(2):283–96. doi: 10.15789/2220-7619-ASB-1699
Review
For citations:
Kurylev A.A., Zhuravkov A.A., Kolbin A.S. Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2021;(4):80-84. (In Russ.) https://doi.org/10.37489/2588-0519-2021-4-80-84
Views:
838
Email this article 